1448237-05-5 Usage
General Description
Naquotinib (mesylate) is a chemical compound that belongs to a class of drugs known as kinase inhibitors. It is specifically designed to target and inhibit a certain type of protein called the epidermal growth factor receptor (EGFR) tyrosine kinase, which plays a critical role in the growth and spread of cancer cells. By blocking the activity of EGFR, Naquotinib (mesylate) can help to prevent the uncontrolled growth and division of cancer cells, ultimately leading to the suppression of tumor growth. It is currently being investigated for its potential use in the treatment of various types of cancer, including non-small cell lung cancer and other solid tumors that are driven by EGFR mutations. Its mechanism of action and potential therapeutic benefits make Naquotinib (mesylate) a promising candidate for the development of new cancer treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 1448237-05-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,4,8,2,3 and 7 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1448237-05:
(9*1)+(8*4)+(7*4)+(6*8)+(5*2)+(4*3)+(3*7)+(2*0)+(1*5)=165
165 % 10 = 5
So 1448237-05-5 is a valid CAS Registry Number.
1448237-05-5Relevant articles and documents
PYRAZINECARBOXAMIDE COMPOUND
-
Paragraph 0443; 0471, (2014/11/11)
[Problem] A compound which is useful as an inhibitor on EGFR T790M mutation kinase activity is provided. [Means for Solution] The present inventors have investigated a compound having an inhibitory action on an EGFR T790M mutation kinase, and have found that a pyrazinecarboxamide compound has an inhibitory action on an EGFR T790M mutation kinase, thereby completing the present invention. The pyrazinecarboxamide compound of the present invention has an inhibitory action on an EGFR T790M mutation kinase, and can be used as an agent for preventing and/or treating EGFR T790M mutation positive cancer, in another embodiment, EGFR T790M mutation positive lung cancer, in a still other embodiment, EGFR T790M mutation positive non-small cell lung cancer, in further still another embodiment, EGFR T790M mutation protein positive cancer, in further still another embodiment, EGFR T790M mutation protein positive lung cancer, in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant cancer, in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant lung cancer, and in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer, or the like.
